Literature DB >> 18370457

Effect of pentoxifylline in vitro on neutrophil reactive oxygen production and phagocytic ability assessed by flow cytometry.

C Wenisch1, K Zedtwitz-Liebenstein, B Parschalk, W Graninger.   

Abstract

Neutrophil granulocytes have been described as agents of defence and destruction. The effect of pentoxifylline on the phagocytic ability and generation of reactive oxygen radicals of neutrophils was studied at concentrations of 1, 10 and 100 mg/L. Flow cytometry was used to study phagocytic ability by measuring uptake of fluorescein-labelled bacteria. The generation of reactive oxygen intermediates was estimated by the quantification of the intracellular conversion of dihydrorhodamine 123 to rhodamine 123. In vitro pentoxifylline treatment diminished neutrophil reactive oxygen production (at 10 mg/L -45% and at 100 mg/L -63%; p < 0.001 for both) and reduced neutrophil phagocytic ability (at 100 mg/L -23%; p < 0.05). Both effects were rapidly reversible after plasma exchange. We conclude that pentoxifylline could decrease oxidative tissue damage by neutrophils in septicaemia or after IV granulocyte transfusion.

Entities:  

Year:  1997        PMID: 18370457     DOI: 10.2165/00044011-199713020-00006

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  15 in total

Review 1.  Pentoxifylline in severe inflammatory response syndrome.

Authors:  W Graninger; C Wenisch
Journal:  J Cardiovasc Pharmacol       Date:  1995       Impact factor: 3.105

Review 2.  Inhibitors of complement and neutrophils: a critical evaluation of their role in the treatment of sepsis.

Authors:  R C Bone
Journal:  Crit Care Med       Date:  1992-06       Impact factor: 7.598

3.  CD11/CD18-independent transendothelial migration of human polymorphonuclear leukocytes and monocytes: involvement of distinct and unique mechanisms.

Authors:  A C Issekutz; H E Chuluyan; N Lopes
Journal:  J Leukoc Biol       Date:  1995-04       Impact factor: 4.962

4.  Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells.

Authors:  B N Cronstein; M A Eberle; H E Gruber; R I Levin
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-15       Impact factor: 11.205

5.  Arachidonic acid metabolism and the adhesion of human polymorphonuclear leukocytes to cultured vascular endothelial cells.

Authors:  M R Buchanan; M J Vazquez; M A Gimbrone
Journal:  Blood       Date:  1983-10       Impact factor: 22.113

6.  Effects of pentoxifylline on human polymorphonuclear neutrophil responses to TNF in whole blood.

Authors:  C Elbim; M Lefebvre; J Hakim; M A Gougerot-Pocidalo
Journal:  Eur Cytokine Netw       Date:  1995 Mar-Apr       Impact factor: 2.737

7.  Inhibition of the inflammatory action of interleukin-1 and tumor necrosis factor (alpha) on neutrophil function by pentoxifylline.

Authors:  G W Sullivan; H T Carper; W J Novick; G L Mandell
Journal:  Infect Immun       Date:  1988-07       Impact factor: 3.441

8.  Polymorphonuclear leucocyte dysregulation in patients with gram-negative septicaemia assessed by flow cytometry.

Authors:  C Wenisch; P Parschalk; M Hasenhündl; A Griesmacher; W Graninger
Journal:  Eur J Clin Invest       Date:  1995-06       Impact factor: 4.686

9.  Pentoxifylline modulates activation of human neutrophils by amphotericin B in vitro.

Authors:  G W Sullivan; H T Carper; G L Mandell
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

10.  Effect of cefodizime and ceftriaxone on phagocytic function in patients with severe infections.

Authors:  C Wenisch; B Parschalk; M Hasenhündl; E Wiesinger; W Graninger
Journal:  Antimicrob Agents Chemother       Date:  1995-03       Impact factor: 5.191

View more
  1 in total

1.  Role of pentoxifylline and sparfloxacin in prophylaxis of spontaneous bacterial peritonitis in cirrhotic patients.

Authors:  Tarek Mohammed Mostafa; Osama Mohamed Ibrahim; Gamal Abd El-Khalek Badra; Mahmoud Samy Abdallah
Journal:  ISRN Gastroenterol       Date:  2014-03-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.